DNA Biomed Solns Cash Flow-to-Debt Ratio
DNA Biomed Solns cash flow-to-debt ratio. DNA Biomed Solns (DNA) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2023, meaning its operating cash flow of ILA-265.00K could theoretically repay 0% of its total liabilities (ILA1.67 Million) in one year. Check total reinvestment intensity of DNA Biomed Solns to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of DNA Biomed Solns (2013–2024)
Cash flow-to-debt ratio of DNA Biomed Solns from 2013 to 2024. Historical debt coverage capacity for DNA Biomed Solns across 12 annual periods. Check DNA Biomed Solns cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
DNA Biomed Solns Cash Flow-to-Debt Ratio by Year (2013–2024)
DNA Biomed Solns cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for DNA Biomed Solns. For the full cash flow conversion analysis, see DNA cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | ILA1.61 Million | ILA2.81 Million | ▲ +224.1% |
| 2023 | -0.46x | ILA-678.00K | ILA1.47 Million | ▼ -145.0% |
| 2022 | -0.19x | ILA-354.00K | ILA1.88 Million | ▲ +97.7% |
| 2021 | -8.12x | ILA-2.33 Million | ILA287.00K | ▼ -13914.7% |
| 2020 | -0.06x | ILA-611.00K | ILA10.54 Million | ▲ +63.9% |
| 2019 | -0.16x | ILA-1.37 Million | ILA8.55 Million | ▼ -52.9% |
| 2018 | -0.11x | ILA-1.66 Million | ILA15.81 Million | ▲ +50.4% |
| 2017 | -0.21x | ILA-1.91 Million | ILA8.99 Million | ▼ -80.2% |
| 2016 | -0.12x | ILA-14.30 Million | ILA121.59 Million | ▲ +72.7% |
| 2015 | -0.43x | ILA-15.57 Million | ILA36.10 Million | ▼ -8.6% |
| 2014 | -0.40x | ILA-10.99 Million | ILA27.68 Million | ▲ +29.5% |
| 2013 | -0.56x | ILA-5.17 Million | ILA9.19 Million | — |